Top Story Today
The First Drug to Cross the Blood-Brain Barrier Just Got FDA Approval. Here's Why That Matters for All of Neuroscience.
The FDA granted accelerated approval to Denali Therapeutics' Avlayah, the first enzyme therapy that actually crosses the blood-brain barrier, for kids with Hunter syndrome. Patients in the Phase 1/2 trial saw a 91% reduction in toxic brain sugar levels by week 24, with cognitive and hearing improvements at two years. Denali's trick: fusing the enzyme to an antibody fragment that hijacks the brain's iron transport system, boosting brain exposure more than 10- to 30-fold. The company also scored a Rare Pediatric Disease Priority Review Voucher (historically worth $100M+).
Why it matters: This isn't just a win for Hunter syndrome. It validates Denali's Transport Vehicle platform as a viable way to ferry drugs past the blood-brain barrier, a problem that has buried countless therapies over the decades. If you can sneak one enzyme through, you can potentially sneak others, opening a new chapter for CNS drug development.
Read more →Deals and Strategy
Merck Drops $6.7 Billion on a Drug That Hasn't Finished Phase 2
With Keytruda's $31.7 billion in annual sales facing patent expiration in late 2028, Merck is paying $6.7 billion (all cash, 42% premium) for Terns Pharmaceuticals and its early-stage CML drug TERN-701. The deal follows a $9.2 billion Cidara acquisition and fits CEO Rob Davis' stated goal of $70 billion in new revenue by the mid-2030s. Analysts are split on whether the price is justified for a drug still in Phase 1/2.
Read more →Innate Pharma Killed the NK Cell Program It Was Named After
The Marseille biotech walked away from its IPH6501 NK cell engager, the technology it spent two decades building. With cash lasting only until Q3 2026 and Sanofi already deprioritizing two other ANKET programs, Innate is betting everything on three surviving assets, headlined by lacutamab's Breakthrough Therapy Designation in rare skin cancer.
Read more →Clinical and Regulatory
Maze Called Its Data 'Best-in-Class.' The Stock Cratered Anyway.
Maze Therapeutics dropped Phase 2 kidney disease data showing a 35.6% reduction in protein leakage (a key kidney damage marker) and zero serious adverse events. Management called it potentially best-in-class. Investors sold hard. The culprits: a 12-patient sample size, open-label design, and a company narrative that set expectations the numbers couldn't fully meet.
Read more →The Lung Infection Nobody Talks About Just Got a Frontline Treatment Option
Insmed's Phase 3b ENCORE trial hit its primary endpoint, showing ARIKAYCE plus standard antibiotics significantly improved respiratory symptoms in newly diagnosed MAC lung disease patients at 13 months. The drug is currently approved only for refractory cases; positive data in first-line patients could unlock a supplemental FDA filing in late 2026 and dramatically expand the commercial opportunity.
Read more →Funding and Financings
This Startup Wants to Zap Your Gut to Treat Diabetes. It Just Raised $50 Million.
Plymouth, Minnesota-based Endogenex closed $50 million to fund its ReCET System, a device that delivers electrical pulses to the duodenum to "factory reset" inflamed gut tissue linked to type 2 diabetes. Born out of a Mayo Clinic partnership and backed by Intuitive Ventures, the company has FDA Breakthrough Device Designation and a rigorous sham-controlled pivotal trial underway.
Read more →AbbVie Paid $1.2B for Their Lead Drug. The Team Kept Everything Else and Raised $60M.
Gilgamesh Pharma, spun out after AbbVie acquired its psychedelic depression drug bretisilocin, closed an oversubscribed $60 million Series A. The pipeline includes blixeprodil, an oral NMDA antagonist with positive Phase 2a data that could rival ketamine for depression (without the clinic visit), plus a cardio-safe ibogaine analog entering Phase 1 in 2026.
Read more →A Stealth Biotech Emerges With $87 Million to Unclog Hearts
Immutrin emerged with an oversubscribed $87 million Series A led by Frazier Life Sciences. The company is developing an antibody that doesn't just stop new amyloid deposits from forming in the heart; it actively removes the ones already there. Think: cleanup crew, not just a "no littering" sign.
Read more →